In reply to Swain et al.: Re-evaluation of updated meta-analysis including trials RTOG 1016 and De-ESCALaTE

The Original Article was published on 25 April 2019

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Swain M, Gupta T, Kannan S, Agarwal J (2019) Cisplatin-based chemoradiotherapy trumps cetuximab-based bioradiotherapy in p16/HPV-positive oropharyngeal cancers. Eur Arch Otorhinolaryngol. https://doi.org/10.1007/s00405-019-05441-5

    Article  PubMed  Google Scholar 

  2. 2.

    Suton P, Skelin M, Rakusic Z, Dokuzovic S, Luksic I (2019) Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE. Eur Arch Oto-Rhino-Laryngol 276:1275–1281. https://doi.org/10.1007/s00405-019-05387-8

    Article  Google Scholar 

  3. 3.

    Riaz N, Baschnagel A, Adkins D, Rao S, Huang J, Chen P et al (2014) Multi-institution analysis of concurrent chemoradiation therapy with cisplatin (CDDP) versus cetuximab (C225) in locally advanced squamous cell carcinoma of the head and neck (LAHNSCC): can HPV help decide which agent? Int J Radiat Oncol Biol Phys 88:472

    Article  Google Scholar 

  4. 4.

    Suton P, Skelin M, Luksic I (2018) Concurrent cisplatin-based chemoradiotherapy versus cetuximab-based bioradiotherapy for p16-positive, locally advanced oropharyngeal cancer: a meta-analysis. Ann Oncol 29(suppl_8):viii372–viii399. https://doi.org/10.1093/annonc/mdy287

    Article  Google Scholar 

  5. 5.

    Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578

    Article  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Petar Suton.

Ethics declarations

Conflict of interest

We disclose any commercial associations that might pose a potential, perceived or real conflict of interest with the content of this article. These include grants, patent licensing arrangements, consultancies, stock or other equity ownership, donations, advisory board memberships, or payments for conducting or publicizing the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Suton, P., Skelin, M., Rakusic, Z. et al. In reply to Swain et al.: Re-evaluation of updated meta-analysis including trials RTOG 1016 and De-ESCALaTE. Eur Arch Otorhinolaryngol 276, 2113–2114 (2019). https://doi.org/10.1007/s00405-019-05485-7

Download citation